Dutch biotechnology company Crucell N.V. (Leiden, the Netherlands, www.crucell.com), the Aeras Global TB Vaccine Foundation (Rockville, MD, www.aeras.org) and the South African Tuberculosis Vaccine Initiative (SATVI, Cape Town, South Africa, www.satvi.uct.ac.za) at the University of Cape Town, recently announced the launch of a new Phase 1 clinical trial of the AdVac-based tuberculosis vaccine, six months after launching a similar study in the US.
Dutch biotechnology company Crucell N.V. (Leiden, the Netherlands, www.crucell.com), the Aeras Global TB Vaccine Foundation (Rockville, MD, www.aeras.org) and the South African Tuberculosis Vaccine Initiative (SATVI, Cape Town, South Africa, www.satvi.uct.ac.za) at the University of Cape Town, recently announced the launch of a new Phase 1 clinical trial of the AdVac-based tuberculosis vaccine, six months after launching a similar study in the US. The trial will be conducted in the Boland-Overberg region of Western Cape Province in South Africa, which has one of the world’s highest TB burdens. Aeras and Crucell began jointly developing this vaccine candidate, called AERAS-402, in 2004 using Crucell’s AdVac vaccine technology and PER.C6 manufacturing technology.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.